August 10, 2023

---

Cibus reports second quarter 2023 financial results and provides business update

June 1, 2023

---

Cibus announces closing of merger with Calyxt to create industry leading precision gene editing and trait development company

May 19, 2023

---

Calyxt announces stockholder approval of merger with Cibus - Calyxt announces 1-for-5 reverse stock split of common stock

May 2, 2023

---

Calyxt reports first quarter 2023 financial results and provides corporate update

April 25, 2023

---

Calyxt completes one-for-ten reverse stock split

April 20, 2023

---

Calyxt, Inc. announces effectiveness of registration statement on Form S-4 in connection with merger with Cibus Global LLC

April 7, 2023

---

Calyxt announces effective date of reverse stock split

March 2, 2023

---

Calyxt reports fourth quarter 2022 financial results and provides corporate update

February 16, 2023

---

Calyxt, Inc. announces its filing of registration statement on Form S-4 in connection with merger with Cibus Global LLC

January 17, 2023

---

Calyxt and Cibus announce definitive merger agreement to create industry-leading precision gene editing and trait licensing company

November 18, 2022

---

Calyxt achieves phase 1 milestone in collaboration agreement to develop an improved soybean capable of producing an oil as a commercial alternative to palm oil

Calyxt granted 180-day extension by Nasdaq to regain compliance with Bid Price Rule

November 3, 2022

---

Calyxt reports third quarter 2022 financial results and provides corporate update

November 2, 2022

---

Calyxt joins Bioindustrial Manufacturing and Design Ecosystem (BioMADE), a Department of Defense initiative, to advance sustainable plant-based biomanufacturing

October 6, 2022

---

Calyxt announces agreement with Evologic Technologies to scale production of its plant-based ingredients

September 22, 2022

---

Calyxt, Inc. exploring strategic alternatives

August 4, 2022

---

Calyxt reports second quarter 2022 financial results and provides corporate update

May 5, 2022

---

Calyxt reports first quarter 2022 financial results

April 26, 2022

---

Calyxt announces strategic hires in business development and manufacturing

March 3, 2022

---

Calyxt reports fourth quarter and full year 2021 financial results

February 23, 2022

---

Calyxt announces closing of SEC-registered offering of common stock, pre-funded warrants to purchase common stock and warrants to purchase common stock

February 7, 2022

---

Calyxt appoints Gerry Nuovo as Senior Vice President of Business Development

Calyxt announces that its pilot BioFactory production system is now operational

January 6, 2022

---

Calyxt announces that its Pilot BioFactory production system is now operational

December 8, 2021

---

Calyxt identifies more than 15,000 unique chemical signatures in lab-scale BioFactory production run

December 6, 2021

---

Calyxt announces strategic hires in artificial intelligence & machine learning and technology licensing

November 4, 2021

---

Calyxt reports third quarter 2021 financial results

October 12, 2021

---

Calyxt names IBM’s Global Chief Artificial Intelligence Officer, Dr. Seth Dobrin, to Scientific Advisory Board

October 5, 2021

---

Calyxt announces new strategic direction to provide sustainable, plant-based synthetic biology solutions to expanded group of end markets and diversified base of customers

September 28, 2021

---

Calyxt announces collaboration with leading global food ingredient manufacturer to develop palm oil alternative - Represents latest partner-driven innovation to leverage Calyxt’s technology platform and expertise in engineering plant-metabolism